Research Progress in the Role of Hypoxia-Inducible Factor 1 in Altitude Sickness and the Mechanisms Involved

ZHOU Zhihao, SUN Fanli, JIANG Binghua

Abstract

Individuals who reside at high altitudes for extended periods or those who visit these regions briefly frequently experience high-altitude response, which triggers a series of physiological and pathological changes in the body, ultimately causing altitude sickness. One of the most critical features of high-altitude environments is hypoxia. Recent studies have demonstrated that hypoxia-inducible factor 1 (HIF-1) plays a central role in mediating the body's response to hypoxic conditions at high altitudes. HIF-1, a heterodimeric transcription factor composed of an oxygen-sensitive subunit α (HIF-1α) and a constitutively expressed subunit β (HIF-1β), directly regulates the expression of multiple target genes, thereby modulating various physiological processes essential for cellular adaptation to hypoxia. According to a substantial body of research, aberrant expression of HIF-1 is implicated in the pathogenesis and progression of various diseases, including altitude sickness, cardiovascular disorders, neurological conditions, inflammatory diseases, cognitive impairment, immune dysregulation, and cancer. In this review, we provided an in-depth examination of the structural characteristics and regulatory mechanisms governing HIF-1 expression, discussed its downstream target genes, and highlighted the inhibitors currently under development. Additionally, we summarized the pivotal role and underlying mechanisms of HIF-1 in the development of altitude sickness, particularly its regulatory role in the pathophysiological processes of high-altitude pulmonary edema (HAPE), high-altitude cerebral edema (HACE), and high-altitude pulmonary hypertension (HAPH). Through a thorough examination of the role of HIF-1, we aim to provide a theoretical foundation and potential therapeutic targets for the prevention and treatment of altitude sickness.

 

Keywords: High-altitude environment, Hypoxia, HIF-1,Altitude sickness, Review

 

Full Text:

PDF


References


PERSSON P B, BONDKE P A. Altitude sickness and altitude adaptation. Acta Physiol (Oxf), 2017, 220(3): 303-306. doi: 10.1111/apha.12894.

GATTERER H, VILLAFUERTE F C, ULRICH S, et al. Altitude illnesses. Nat Rev Dis Primers, 2024, 10(1): 43. doi: 10.1038/s41572-024-00526-w.

LEE P, CHANDEL N S, SIMON M C. Cellular adaptation to hypoxia through hypoxia inducible factors and beyond. Nat Rev Mol Cell Biol, 2020, 21(5): 268-283. doi: 10.1038/s41580-020-0227-y.

RASHID M, ZADEH L R, BARADARAN B, et al. Up-down regulation of HIF-1alpha in cancer progression. Gene, 2021, 798: 145796. doi: 10.1016/j.gene.2021.145796.

PIASECKA D, BRAUN M, MIESZKOWSKA M, et al. Upregulation of HIF1-alpha via an NF-kappaB/COX2 pathway confers proliferative dominance of HER2-negative ductal carcinoma in situ cells in response to inflammatory stimuli. Neoplasia, 2020, 22(11): 576-589. doi: 10.1016/j. neo.2020.09.003.

DAVERIO Z, BALCERCZYK A, RAUTUREAU G, et al. How Warburg-Associated Lactic Acidosis Rewires Cancer Cell Energy Metabolism to Resist Glucose Deprivation. Cancers (Basel), 2023, 15(5):1417. doi: 10.3390/cancers15051417.

WANG G L, SEMENZA G L. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood, 1993, 82(12): 3610-3615. doi: 10.1182/blood.V82.12.3610.3610.

SEMENZA G L, WANG G L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol, 1992, 12(12): 5447-5454. doi: 10.1128/mcb.12.12.5447-5454.1992.

WANG G L, SEMENZA G L. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem, 1995, 270(3): 1230-1237. doi: 10. 1074/jbc.270.3.1230.

YANG J, ZHANG L, ERBEL P J, et al. Functions of the Per/ARNT/Sim domains of the hypoxia-inducible factor. J Biol Chem, 2005, 280(43): 36047-36054. doi: 10.1074/jbc.M501755200.

WANG G L, JIANG B H, RUE E A, et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A, 1995, 92(12): 5510-5514. doi: 10.1073/pnas.92. 12.5510.

MAXWELL P H, WIESENER M S, CHANG G W, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature, 1999, 399(6733): 271-275. doi: 10.1038/ 20459.

APPELHOFF R J, TIAN Y M, RAVAL R R, et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem, 2004, 279(37): 38458-38465. doi: 10.1074/jbc.M406026200.

KIM W Y, SAFRAN M, BUCKLEY M R, et al. Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo. Embo J, 2006, 25(19): 4650-4662. doi: 10.1038/sj. emboj.7601300.

RATCLIFFE P J, O'ROURKE J F, MAXWELL P H, et al. Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression. J Exp Biol, 1998, 201(Pt 8): 1153-1162. doi: 10.1242/jeb.201.8. 1153.

ZHOU Q, LIU L Z, FU B, et al. Reactive oxygen species regulate insulin-induced VEGF and HIF-1alpha expression through the activation of p70S6K1 in human prostate cancer cells. Carcinogenesis, 2007, 28(1): 28-37. doi: 10.1093/carcin/bgl085.

GUO S, BRAGINA O, XU Y, et al. Glucose up-regulates HIF-1 alpha expression in primary cortical neurons in response to hypoxia through maintaining cellular redox status. J Neurochem, 2008, 105(5): 1849-1860. doi: 10.1111/j.1471-4159.2008.05287.x.

JIANG B H, AGANI F, PASSANITI A, et al. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res, 1997, 57(23): 5328-5335.

KIM J W, TCHERNYSHYOV I, SEMENZA G L, et al. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab, 2006, 3(3): 177-185. doi: 10.1016/j.cmet.2006.02.002.

Van UDEN P, KENNETH N S, ROCHA S. Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. Biochem J, 2008, 412(3): 477-484. doi: 10.1042/BJ20080476.

SALNIKOW K, KASPRZAK K S. Ascorbate depletion: a critical step in nickel carcinogenesis? Environ Health Perspect, 2005, 113(5): 577-584. doi: 10.1289/ehp.7605.

SCHREIBER T, SCHARNER B, THEVENOD F. Insoluble HIFa protein aggregates by cadmium disrupt hypoxia-prolyl hydroxylase (PHD)-hypoxia inducible factor (HIFa) signaling in renal epithelial (NRK-52E) and interstitial (FAIK3-5) cells. Biometals, 2024, 37(6): 1629-1642. doi: 10.1007/s10534-024-00631-z.

CHEN Q Y, MURPHY A, SUN H, et al. Molecular and epigenetic mechanisms of Cr(VI)-induced carcinogenesis. Toxicol Appl Pharmacol, 2019, 377: 114636. doi: 10.1016/j.taap.2019.114636.


Refbacks

  • There are currently no refbacks.